Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Candel’s multimodal immunotherapies have been shown to convert ‘cold’ solid tumors into ‘hot’ tumors (most recent publication: Nature, 2023 vol. 623(7985) pp. 157-166
@"Why every decision we take – especially the hardest ones – revolve around patients." on @LinkedIn
‘Execution is the hard part of a business’.
Very true and the critical importance of this is often undervalued - until things go south.
We are pleased to share that @BrighamWomens will present clinical results on our oncolytic virus CAN-3110 in recurrent high-grade glioma, highlighting extended survival associated with immune activation at #SNO2023.
Learn more here: https://sno2023.eventscribe.net/
